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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
Bifidobacterium bifidum CNCM I-3426 and defence against pathogens in 
the upper respiratory tract pursuant to Article 13(5) of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Lallemand Health Solutions, submitted pursuant to Article 13(5) of Regulation 
(EC) No 1924/2006 via the Competent Authority of France, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to 
Bifidobacterium bifidum CNCM I-3426 and defence against pathogens in the upper respiratory tract. The food 
constituent that is the subject of the claim is B. bifidum CNCM I-3426. The Panel considers that B. bifidum 
CNCM I-3426 is sufficiently characterised. The Panel considers that defence against pathogens in the upper 
respiratory tract is a beneficial physiological effect. The applicant provided one published human intervention 
study, one unpublished human intervention study (which was published during the evaluation of the claim) and 
one in vitro study as pertinent to the claimed effect. The Panel considers that no conclusions can be drawn from 
either of the human studies for the scientific substantiation of the claim. In the absence of evidence of an effect 
of B. bifidum CNCM I3426 on defence against pathogens in the upper respiratory tract in humans, the results of 
the in vitro study submitted cannot be used as a source of data for the scientific substantiation of the claim. The 
Panel concludes that a cause and effect relationship has not been established between the consumption of 
B. bifidum CNCM I-3426 and defence against pathogens in the upper respiratory tract. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following an application from Lallemand Health Solutions, submitted pursuant to Article 13(5) of 
Regulation (EC) No 1924/2006 via the Competent Authority of France, the Panel on Dietetic Products, 
Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a 
health claim related to Bifidobacterium bifidum CNCM I-3426 and defence against pathogens in the 
upper respiratory tract. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application includes a request for the protection of proprietary data. 
The food constituent that is the subject of the health claim is B. bifidum CNCM I-3426. The Panel 
considers that B. bifidum CNCM I-3426 is sufficiently characterised. 
The claimed effect proposed by the applicant is that B. bifidum CNCM I-3426 can lead to an “increase 
of the proportion of healthy days (i.e. days without cold symptoms) by maintaining normal immune 
function in healthy adults during everyday life events such as moderate stress”. Upon a request from 
EFSA for clarification, the applicant explained that the claimed effect refers to defence against 
pathogens in the upper respiratory tract. The target population, as proposed by the applicant, is the 
general population. The Panel considers that defence against pathogens in the upper respiratory tract is 
a beneficial physiological effect. 
The applicant provided one published human intervention study, one unpublished human intervention 
study (which was published during the evaluation of the claim) and one in vitro study as pertinent to 
the claimed effect. 
One human intervention study was performed with a food which did not comply with the 
specifications provided for the food that is the subject of the health claim. The other human 
intervention study did not provide information on the effect of the food (i.e. B. bifidum CNCM I-3426) 
on clinical outcomes related to upper respiratory infections (e.g. incidence, severity and/or duration of 
symptoms) which could be used for the scientific substantiation of the claim of defence against 
pathogens in the upper respiratory tract. The Panel also notes that the post-hoc, between-arm statistical 
analyses provided for the primary outcome were not justified. The Panel considers that no conclusions 
can be drawn from either of the human studies for the scientific substantiation of the claim. 
In the absence of evidence of an effect of B. bifidum CNCM I3426 on defence against pathogens in the 
upper respiratory tract in humans, the results of the in vitro study submitted cannot be used as a source 
of data for the scientific substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of B. bifidum CNCM I-3426 and defence against pathogens 
in the upper respiratory tract. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the Community 
list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
The application was received on 19/09/2014. 
 The scope of the application was proposed to fall under a health claim referring to disease risk 
reduction. 
 The scientific evaluation procedure started on 08/12/2014. 
 On 21/01/2015, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the clock 
was stopped on 16/02/2015, in compliance with Art. 18(3) of Regulation (EC) No 1924/2006. 
 On 02/03/2015, EFSA received the applicant’s reply as submitted by the applicant and the 
clock was restarted. 
 During its meeting on 22/04/2015, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to B. bifidum 
CNCM I-3426 and defence against pathogens in the upper respiratory tract. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion 
on the scientific substantiation of a health claim related to B. bifidum CNCM I-3426 and defence 
against pathogens in the upper respiratory tract. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of B. bifidum CNCM I-3426, a positive assessment of its safety, nor a decision on whether B. bifidum 
CNCM I-3426 is, or is not, classified as a foodstuff. It should be noted that such an assessment is not 
foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address  
Lallemand Health Solutions, 17975 rue des Gouverneurs, Mirabel, Quebec, Canada, J7J 2K7. 
The application contains a request for the protection of proprietary data from an unpublished 
Langkamp-Henken and Dahl (2014) study report, in accordance with Article 21 of Regulation (EC) 
No 1924/2006. 
Food as stated by the applicant 
According to the applicant, the food for which this health claim is made is Bifidobacterium bifidum 
CNCM I-3426. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect refers to an increase of the proportion of healthy days 
(i.e. days without cold symptoms) by maintaining normal immune function in healthy adults during 
everyday life events such as moderate stress. The mechanisms of action of probiotics with regard to 
the management of upper respiratory tract infections, like cold and flu, have not yet been confirmed. 
Nevertheless, various potential mechanisms have been proposed, based on evidence from in vitro, 
animal and human studies, including an enhancement of barrier function, the production of 
antimicrobial substances and immunomodulatory effects. Upon a request from EFSA, the applicant 
explained that the claimed effect relates to defence against pathogens in the upper respiratory tract. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Bifidobacterium bifidum 
CNCM I-3426 increases the proportion of healthy days by maintaining normal immune function in 
healthy adults during everyday life events such as moderate stress”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed that the quantity required to obtain the claimed effect is between 
3 × 10
9
 colony-forming units (CFU) and 7  109 CFU per day. This quantity can be obtained by the 
consumption of one capsule daily containing 5 × 10
9
 CFU of Bifidobacterium bifidum CNCM I-3426. 
The proposed target population is the general population. 
ASSESSMENT 
1. Characterisation of the food 
The applicant stated that the food that is the subject of the health claim is Bifidobacterium bifidum 
CNCM I-3426 (also named B. bifidum R0071). The bacterial strain was deposited in the “Collection 
Nationale de Cultures de Microorganismes” (CNCM) under the deposit number I-3426. The CNCM is 
a restricted-access non-public collection which has the status of International Depositary Authority 
under the Budapest Treaty. Data on the phenotypic (morphology and biochemical test results) and 
genotypic characterisation of the species and strain, including 16S ribosomal DNA and tuf gene 
sequence analyses for species identification, and pulse field gel electrophoresis and random 
amplification of polymorphic DNA for strain typing, were provided. 
Information about the manufacturing process and stability was also provided. 
The Panel considers that the food, B. bifidum CNCM I-3426, which is the subject of the health claim, 
is sufficiently characterised. 
B. bifidum CNCM I-3426 and defence against pathogens in the respiratory tract     
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2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is that B. bifidum CNCM I-3426 can lead to an “increase 
of the proportion of healthy days (i.e. days without cold symptoms) by maintaining normal immune 
function in healthy adults during everyday life events such as moderate stress”. The target population 
proposed by the applicant is the general population. In response to a request from EFSA, the applicant 
explained that the claimed effect refers to defence against pathogens in the upper respiratory tract. 
Scientific evidence for the substantiation of health claims related to defence against pathogens in the 
respiratory tract can be obtained from human intervention studies showing an effect on clinical 
outcomes related to respiratory infections (e.g. incidence, severity and/or duration of symptoms), of 
either the upper respiratory tract (such as rhinitis, pharyngitis, sinusitis, otitis or the common cold) or 
the lower respiratory tract (such as pneumonia, bronchitis or bronchiolitis), or both (EFSA NDA 
Panel, 2015). 
The Panel considers that defence against pathogens in the upper respiratory tract is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search using Medline and Google Scholar databases with the 
following search terms: “Bifidobacterium bifidum CNCM I-3426” OR “Bifidobacterium bifidum 
R0071” OR “Bifidobacterium bifidum R71” OR “Bifidobacterium bifidum Rosell-71”. One published 
human study (Cazzola et al., 2010), claimed by the applicant as pertinent to the health claim, was 
identified through the literature search. Additionally, one unpublished human intervention study 
(Langkamp-Henken and Dahl, unpublished) and one unpublished non-human study (MacPherson et 
al., unpublished) were submitted by the applicant as pertinent to the claim. The Panel notes that the 
results of one of these studies were published during the evaluation of the claim (Langkamp-Henken et 
al., 2015). 
Cazzola et al. (2010), in a multi-centre, randomised, double-blind, placebo-controlled, parallel 
intervention study, assessed the effect of consuming a combination of three bacterial strains 
(Lactobacillus helveticus R0052, Bifidobacterium infantis R0033 and B. bifidum CNCM I-3426) plus 
fructo-oligosaccharides on the incidence of infections in 135 children. The Panel notes that this study 
was performed with a food which did not comply with the specifications provided for the food that is 
the subject of the health claim (see Section 1). The Panel considers that no conclusions can be drawn 
from this study for the scientific substantiation of the claim. 
In a single-centre, randomised, parallel, double-blind, four-arm, placebo-controlled study (Langkamp-
Henken et al., 2015), the effects of three individual bacterial strains (B. bifidum CNCM I-3426, 
Bifidobacterium longum subsp. infantis R0033 and Lactobacillus helveticus R0052), given in capsules 
for six weeks (one capsule containing 3 × 10
9
 CFU of the particular bacterial strain per day), were 
assessed against placebo capsules (magnesium stearate and potato starch) in a group of apparently 
healthy students (n = 581 randomised subjects, mean age 20 years, 371 females; 142 subjects in 
B. bifidum CNCM I-3426 group, 147 subjects in B. longum subsp. infantis R0033 group, 145 subjects 
in L. helveticus R0052 group and 147 subjects in placebo group) potentially under psychological stress 
during their autumn academic exams. The exams were held over a one-week period during the fourth 
or fifth week of the intervention. The percentage of subjects vaccinated against influenza varied from 
28 to 38 % among the groups. Subjects who were taking medicines for allergic symptoms and had 
received antibiotic therapy in the two months prior to the study were excluded. 
Online questionnaires were compiled daily by the subjects in order to gather information about cold 
and flu symptoms. The proportion of healthy days was evaluated using a modified Jackson scale 
which included nine questions about cold symptoms (running/congested nose, stiffness or chills, 
headache, cough, fatigue, fever, sore throat, achiness and ear discomfort) and symptom intensity 
(scores: 0 = no symptoms to 3 = severe symptoms). A day was considered as “healthy” if the sum of 
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the cold symptom intensity scores was ≤ 6. Participants were asked not to record symptoms which 
could be attributed to allergy. The same questionnaire was also used to calculate the number of 
participants reporting at least one day with cold/flu symptoms (cold symptom intensity score > 6), the 
number of episodes of cold/flu and the duration of cold/flu. 
The Panel notes that the original Jackson scale (Jackson et al., 1958), which was validated for the 
diagnosis of common cold episodes, includes the rating of the following common cold symptoms on a 
4-point scale: sneezing, headaches, malaise, chilliness, nasal discharge, nasal obstruction, sore throat 
and cough. A common cold episode is defined as a symptom score of 14 plus the subject’s subjective 
feeling of illness or increased nasal discharge on three out of six days. For symptom scores < 14, both 
the subject’s subjective feeling of illness and an increased nasal discharge on three out of six days are 
required for diagnosis. The Panel also notes that the “modified” Jackson scale used in the study by 
Langkamp-Henken et al. (2015) includes one more symptom (fatigue), but defines a much lower 
threshold for the diagnosis of a common cold episode. Upon a request from EFSA for clarification on 
whether or not the modified Jackson scale used in the study had been validated for the diagnosis of the 
common cold, the applicant argued that the same questionnaire had been used in a previous study 
(Hughes et al., 2011). The Panel notes that this publication does not contain any information on the 
validation of the modified Jackson scale. The applicant also stated that the study population recruited 
by Langkamp-Henken et al. (2015) was different from the population studied by Jackson et al. (1958), 
and that “a validated questionnaire to assess cold and flu symptoms in healthy populations is absent”. 
The Panel notes that the modified Jackson scale used by Langkamp-Henken et al. (2015) has not been 
validated for the diagnosis of the common cold. The Panel considers that no evidence was provided to 
confirm that the modified Jackson scale, as used in the study, is a valid tool for diagnosis of the 
incidence, severity and/or duration of common cold episodes, and therefore it is unclear how the 
outcome measures derived from this tool relate to the claimed effect on defence against pathogens. 
Numerous primary outcomes, e.g. proportion of “healthy days” (days without cold symptoms), 
symptom intensity score, changes in faecal microbiota, various gastrointestinal symptoms and quality 
of life, were specified. Secondary outcomes comprised salivary immunoglobulin A (IgA), faecal IgA, 
bowel frequency and consistency, and salivary cortisol. In response to a request from EFSA, the 
applicant stated that the proportion of healthy days (i.e. days with a symptom score ≤ 6) was the only 
primary outcome of the study. The Panel notes that the outcome used to calculate the sample size was 
the proportion of days with a symptom score > 6. 
When the results for the primary outcome (i.e. the proportion of days with a symptom score ≤ 6) were 
analysed across all four study groups using a generalised linear model (GLM), no statistically 
significant differences among groups were found. Subsequent analyses, in which each study arm was 
compared with another, were performed by the applicant. The results of these post-hoc analyses were 
only presented for the B. bifidum CNCM I-3426 arm versus the placebo arm. In response to a request 
from EFSA to provide the full study report, the applicant did not provide the study report, but stated 
that only the information related to the intervention with B. bifidum CNCM I-3426 versus placebo was 
relevant for this application. The Panel notes that further between-arm analyses are not justified in the 
absence of a statistically significant difference among the study arms in the overall analysis using a 
GLM. 
The Panel notes that this study does not provide information on the effect of the food (i.e. B. bifidum 
CNCM I-3426) on clinical outcomes related to upper respiratory tract infections (e.g. incidence, 
severity and/or duration of symptoms) which could be used for the scientific substantiation of a claim 
on defence against pathogens in the upper respiratory tract. The Panel also notes that the post-hoc, 
between-arm statistical analyses provided for the primary outcome were not justified. The Panel 
considers that no conclusions can be drawn from this study for the scientific substantiation of the 
claim. 
An in vitro study (MacPherson et al., unpublished) was also provided by the applicant in support of a 
mechanism by which B. bifidum CNCM I-3426 could exert the claimed effect. The Panel considers 
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that, in the absence of evidence of an effect of B. bifidum CNCM I3426 on defence against pathogens 
in the upper respiratory tract in humans, the results of this in vitro study cannot be used as a source of 
data for the scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of B. bifidum CNCM I-3426 and defence against pathogens in the upper respiratory tract. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food product, B. bifidum CNCM I-3426, which is the subject of the health claim, is 
sufficiently characterised. 
 The claimed effect is “defence against pathogens in the upper respiratory tract”. The target 
population, as proposed by the applicant, is the general population. Defence against pathogens 
in the upper respiratory tract is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
B. bifidum CNCM I-3426 and defence against pathogens in the upper respiratory tract. 
DOCUMENTATION PROVIDED TO EFSA 
1. Health claim application on B. bifidum CNCM I-3426 and defence against pathogens in the upper 
respiratory tract pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 
0429_FR). September 2014. Submitted by Lallemand Health Solutions. 
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ABBREVIATIONS 
CFU  colony-forming unit 
CNCM  Collection Nationale de Cultures de Microorganismes 
GLM  generalised linear model 
IgA  immunoglobulin A 
NDA  Dietetic Products, Nutrition and Allergies 
